A Phase I/II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Phase of Trial: Phase I/II
Latest Information Update: 09 Jan 2013
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2012 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 14 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.